{"filing":{"accession_number":"0001193125-26-292834","cik":"0001540171","ticker":"AVLN","company_name":"Avalyn Pharma Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ck0001540171-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526292834/ck0001540171-20260629.htm"},"events":[{"id":15619,"run_id":13923,"accession_number":"0001193125-26-292834","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Avalyn Pharma entered into a First Amendment to a sublease agreement expanding the leased premises from 8,774 to 13,708 rentable square feet with an increase in future minimum lease payments of approximately $924,000 over the remaining lease term. This is a material operational/real estate commitment that does not fit the specific categories of M\u0026A, debt issuance, or other named financial events, making it an operational business arrangement material to investors assessing the company's capital commitments and facility footprint.","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13465,"accession_number":"0001193125-26-292834","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Avalyn Pharma entered into a First Amendment to a sublease agreement expanding the leased premises from 8,774 to 13,708 rentable square feet with an increase in future minimum lease payments of approximately $924,000 over the remaining lease term. This is a material operational/real estate commitment that does not fit the specific categories of M\u0026A, debt issuance, or other named financial events, making it an operational business arrangement material to investors assessing the company's capital commitments and facility footprint.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:18:12.663100+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13465,"accession_number":"0001193125-26-292834","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Avalyn Pharma entered into a First Amendment to a sublease agreement expanding the leased premises from 8,774 to 13,708 rentable square feet with an increase in future minimum lease payments of approximately $924,000 over the remaining lease term. This is a material operational/real estate commitment that does not fit the specific categories of M\u0026A, debt issuance, or other named financial events, making it an operational business arrangement material to investors assessing the company's capital commitments and facility footprint.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T00:18:12.663100+00:00","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-07-01"}]}